Recombinant allergens for immunotherapy

被引：164

作者：

Valenta, Rudolf ^{[1
]}

Niederberger, Verena

机构：

[1] Med Univ Vienna, Christian Doppler Lab Allergy Res, Div Immunopathol, Dept Pathophysiol,Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria

[2] Med Univ Vienna, Dept Otolaryngol, Vienna, Austria

[3] Guys Hosp, Dept Otolaryngol, London SE1 9RT, England

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2007年 / 119卷 / 04期

基金：

奥地利科学基金会;

关键词：

recombinant allergens; immunotherapy;

D O I：

10.1016/j.jaci.2007.01.025

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Recombinant allergens can be produced as defined molecules in consistent quality and unlimited amounts according to the corresponding DNA template. Furthermore, they can be modified to reduce their allergenic activity and to foster certain advantageous immunologic properties. Recombinant allergens equaling the natural allergens are available for diagnostic and therapeutic purposes, and modified versions have been developed with the aim to to reduce IgE-mediated side effects during immunotherapy. First injection immunotherapy trials conducted with recombinant vaccines for birch pollen and grass pollen allergy show that recombinant allergen-based immunotherapy has vaccination characteristics and is clinically effective. The obtained results hold promise that recombinant allergen-based immunotherapy will improve current immunotherapy practice and may open possibilities for new treatment strategies and possibly even for prophylactic vaccination.

引用

页码：826 / 830

页数：5

共 27 条

[21] Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization [J].

Traidl-Hoffmann, C ;

Mariani, V ;

Hochrein, H ;

Karg, K ;

Wagner, H ;

Ring, J ;

Mueller, MJ ;

Jakob, T ;

Behrendt, H .

JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (04) :627-635

[22] From allergen structure to new forms of allergen-specific immunotherapy [J].

Valenta, R ;

Kraft, D .

CURRENT OPINION IN IMMUNOLOGY, 2002, 14 (06) :718-727

[23] The future of antigen-specific immunotherapy of allergy [J].

Valenta, R .

NATURE REVIEWS IMMUNOLOGY, 2002, 2 (06) :446-453

[24] Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1:: Results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season [J].

van Hage-Hamsten, M ;

Kronqvist, M ;

Zetterström, O ;

Johansson, E ;

Niederberger, V ;

Vrtala, S ;

Grönlund, H ;

Grönneberg, R ;

Valenta, R .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 104 (05) :969-977

[25] False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite (Dermatophagoides pteronyssinus) allergens [J].

vanderVeen, MJ ;

Mulder, M ;

Witteman, AM ;

vanRee, R ;

Aalberse, RC ;

Jansen, HM ;

vanderZee, JS .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 98 (06) :1028-1034

[26] Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments - Candidates for a novel form of specific immunotherapy [J].

Vrtala, S ;

Hirtenlehner, K ;

Vangelista, L ;

Pastore, A ;

Eichler, HG ;

Sperr, WR ;

Valent, P ;

Ebner, C ;

Kraft, D ;

Valenta, R .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) :1673-1681

[27] Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1 [J].

Vrtala, S ;

Hirtenlehner, K ;

Susani, M ;

Akdis, M ;

Kussebi, F ;

Akdis, CA ;

Blaser, K ;

Hufnagl, P ;

Binder, BR ;

Politou, A ;

Pastore, A ;

Vangelista, L ;

Sperr, WR ;

Semper, H ;

Valent, P ;

Ebner, C ;

Kraft, D ;

Valenta, R .

FASEB JOURNAL, 2001, 15 (09) :2045-+

← 1 2 3 →